# 10x Genomics, Inc. – Consensus ‘buy’ rating and 49.3% Upside Potential

- Link: https://www.directorstalkinterviews.com/10x-genomics-inc.consensus-buy-rating-and-49.3-upside-potential/4121130972
- Published: 2023-10-26T13:34:37+01:00
- Author: Charlotte Edwards

**10x Genomics, Inc.** with ticker code (TXG) have now 12 market analysts covering
the stock. The analyst consensus now points to a rating of ‘buy’. The range between
the high target price and low target price is between 75 and 30 calculating the 
average target price we see $60.33. Given that the stocks previous close was at 
$40.42 this indicates there is a potential upside of 49.3%. It’s also worth noting
that there is a 50 day moving average of $44.36 and the 200 moving average now moves
to $50.27. The company has a market capitalization of 4.35B. The current share price
for the company is: 37.02 USD

 The potential market cap would be $6,487,959,342 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of 4.93 and
a -11.2% return on assets.

10x Genomics, Inc. is a life science technology company. The Company’s integrated
platform solutions include instruments, consumables and software for analyzing biological
systems. Its Chromium platform includes its Chromium X Series, Chromium Connect 
and legacy Chromium Controller instruments, microfluidic chips and related consumables,
enables throughput analysis of individual biological components. Its Visium platform
enables researchers to understand the spatial positions of biological analytes within
tissues at high resolution. Its products include Chromium Single Cell Gene Expression,
Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling,
Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium
Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, Visium
Spatial Proteogenomics and Xenium In Situ Gene Expression. Its patent portfolio 
comprises over 1,750 issued patents and patent applications.

Share on: